Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The primary aim of this single arm, phase II study is to determine the efficacy of the
combination therapy Pembrolizumab/Lenvatinib regarding the rate of major pathological
response (MPR-Rate). The investigators expect to improve the MPR-Rate of 20% in
Anti-PD1/-PD-L1 monotherapy (observed in recent trials) to a MPR-Rate of 40% with the
combination therapy Pembrolizumab/Lenvatinib.